<DOC>
	<DOCNO>NCT00377182</DOCNO>
	<brief_summary>This 4 arm study compare safety tolerability HCV polymerase inhibitor pro-drug combination PEGASYS +/- COPEGUS standard care therapy PEGASYS + COPEGUS , treatment-naive patient CHC , genotype 1 . Patients randomize receive 1500mg 3000mg po bid HCV polymerase inhibitor pro-drug + PEGASYS , 1500mg HCV polymerase inhibitor pro-drug + PEGASYS + COPEGUS PEGASYS + COPEGUS 4 week . All patient receive least one dose study medication receive open label PEGASYS + Copegus additional 44 week 4 week experimental period . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Hepatitis C Virus ( HCV ) Polymerase Inhibitor Pro-Drug Combination With PEGASYS With Without COPEGUS Patients With Chronic Hepatitis C ( CHC ) Genotype 1 Infection .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , 1865 year age ; CHC without liver cirrhosis incomplete/transition liver cirrhosis , genotype 1 ; chronic liver disease consistent CHC . infection HCV genotype genotype 1 ; previous treatment CHC ; medical condition associate chronic liver disease CHC ; HIV , Hepatitis A , Hepatitis B infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>